Penumbra PEN NYSE · Healthcare · United States
$320.79 -0.29% -$0.93
Summary
64 / 100 · Bulios Score
What speaks for it
- Revenue grew by 18% a year over the last 3 years.
- It holds more cash than debt: $254.3M against $209.4M.
- Out of every 100 USD of revenue, 13 USD is left as free cash.
- Analysts expect revenue to grow by 14% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 80.5 USD for 1 USD of yearly profit. Over the last five years it was 725.6 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 20% a year over 5 years. Over the last 3 years it grew by 18% a year. For the next fiscal year analysts expect revenue to grow by 14%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 32 USD
- Research and development 6.1 USD
- Sales and administration 50 USD
- Taxes and other 2.1 USD
- Net profit 10 USD
Net profit, industry median (Medical - Devices) 6.7 USD
Out of every 100 USD of revenue, 10 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.0 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 9
- Hold 13
- Sell 0
Today's price within the analysts' price targets
The average target of $320 is at today's price. 41% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2022By product
- Peripheral Vascular 59%
- Neuro 41%
By region
- UNITED STATES 78%
- Non-US 22%
Peripheral Vascular brings in 59% of revenue.
Segments in detail